Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. E-therapeutics plc
  6. News
  7. Summary
    ETX   GB00B2823H99


Delayed Quote. Delayed London Stock Exchange - 01/26 11:35:22 am
30 GBX   -4.15%
2021E-Therapeutics CFO to Step Down; Interim Finance Chief Named
2021E-Therapeutics plc Announces Executive Changes
2021Director Dealing – 26th October 2021
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

e therapeutics : RNAi Platform Characterisation Results

10/26/2021 | 02:06am EST

e-therapeutics plc

("e-therapeutics" or the "Company")

RNAi Platform Characterisation Results

Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, today announces the results of the Company's RNAi platform characterisation studies.


  • RNAi platform benchmarking studies successfully completed
  • Equivalent performance to leading competitor platforms
  • Excellent and comparable safety profile seen in lead designs
  • Consistent translation from in vitro to rodent and non-human primates (NHP)
  • Additional six new patent applications filed to protect innovation bringing to a total of eleven

On 1 February 2021, the Company announced the commencement of multiple in vitro and in vivo studies to test newly designed small interfering RNA ("siRNA") delivery moieties (GalNAc conjugates) and novel RNA stabilisation chemistries. Three gene targets expressed in hepatocytes (liver cells) were selected for benchmarking and eight different GalNAc-siRNA construct designs were tested per target. The Company is now pleased to announce that it has successfully established two different GalNAc- siRNA construct designs that have shown at least equivalent performance in terms of potency, target gene silencing and duration of action (up to three months) against the best competitor data in the same targets. Benchmarking studies included one approved RNAi drug and one currently in registration.

To this end, on 11 October 2021 the Company announced that five new patent applications had been filed to protect these novel construct designs and a further six new patent applications have now also been filed. The relevant summary dataset will be presented at the Company's R&D Day in 2022 and headline non-human primate data can be found in the interim results presentation at

e-therapeutics plc (etherapeutics.co.uk)

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "These results are a crucial step forward for the Company. We set a very high hurdle to benchmark our platform against leading peer platforms and we are now confident that our proprietary GalNAc-siRNAtechnology is competitive, having shown equivalent performance. In the space of nine months, e-therapeuticshas achieved what has taken the industry many years to achieve. The Company is now in a position to execute on its ambition of developing an in-housepipeline combining novel target ideas generated using its computational biology platform, and RNAi as a modality."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.


e-therapeutics plc

Tel: +44 (0)1993 883 125

Ali Mortazavi, CEO


Karl Keegan, CFO

SP Angel Corporate Finance LLP

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-ledin silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.


e-Therapeutics plc published this content on 26 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 06:05:02 UTC.

© Publicnow 2021
2021E-Therapeutics CFO to Step Down; Interim Finance Chief Named
2021E-Therapeutics plc Announces Executive Changes
2021Director Dealing – 26th October 2021
2021E THERAPEUTICS : Interim Results, July 2021 and RNAi Platform Development Presentation
2021E THERAPEUTICS : Interim results for six months ended 31 July 2021
2021E THERAPEUTICS : Earnings Flash (ETX.L) E-THERAPEUTICS Reports Fiscal H1 Loss GBX-0.54
2021E THERAPEUTICS : Earnings Flash (ETX.L) E-THERAPEUTICS Reports Fiscal H1 Revenue GBP477,00..
2021E THERAPEUTICS : RNAi Platform Characterisation Results
2021E-therapeutics plc Reports Earnings Results for the Half Year Ended July 31, 2021
2021E-therapeutics plc Announces the Results of the RNAi Platform Characterization Studies
More news
Sales 2021 0,32 M 0,43 M 0,43 M
Net income 2021 -3,68 M -4,96 M -4,96 M
Net cash 2021 13,0 M 17,5 M 17,5 M
P/E ratio 2021 -18,9x
Yield 2021 -
Capitalization 154 M 209 M 208 M
EV / Sales 2020 13,9x
EV / Sales 2021 206x
Nbr of Employees 33
Free-Float 41,6%
Duration : Period :
e-therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends E-THERAPEUTICS PLC
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Ahmad Ali Mortazavi Chief Executive Officer
Michael Anthony Bretherton Chief Financial Officer & Director
Trevor Mervyn Jones Non-Executive Chairman
Laura Roca-Alonso Chief Business Officer
Stephanie Maley Chief People Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875